Ascendis Pharma
Ascendis Pharma A/S, headquartered in Denmark (DK), is a pioneering biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. Founded in 2006, Ascendis has made significant strides in the biopharmaceutical industry, particularly with its TransCon technology platform, which enhances the delivery and efficacy of biologic medicines. The company operates primarily in Europe and North America, with a strong emphasis on creating unique product offerings that address unmet medical needs. Notable achievements include the successful launch of its lead product, TransCon Growth Hormone, which has garnered attention for its potential to improve patient outcomes in growth hormone deficiency. Ascendis Pharma continues to solidify its market position through a commitment to scientific excellence and patient-centric solutions.
DitchCarbon Score
How does Ascendis Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ascendis Pharma's score of 18 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ascendis Pharma's reported carbon emissions
Ascendis Pharma, headquartered in Denmark (DK), currently does not have publicly available carbon emissions data or specific reduction targets. Without concrete figures or commitments, it is challenging to assess their climate impact or initiatives. However, the pharmaceutical industry is increasingly focusing on sustainability and reducing carbon footprints, often aligning with global climate goals. Ascendis Pharma may be expected to engage in similar efforts as part of industry trends, but specific details regarding their emissions or climate commitments remain unspecified.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ascendis Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
